Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell · Sponsor: Novartis Pharmaceuticals
About this study
This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received prior systemic therapy for advanced or metastatic RCC.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (227)
| Novartis Investigative Site | Huntsville, Alabama, United States | — |
| Novartis Investigative Site | Tucson, Arizona, United States | — |
| Novartis Investigative Site | Little Rock, Arkansas, United States | — |
| Novartis Investigative Site | Beverly Hills, California, United States | — |
| Novartis Investigative Site | Escondido, California, United States | — |
| Novartis Investigative Site | Fresno, California, United States | — |
| Novartis Investigative Site | Greenbrae, California, United States | — |
| Novartis Investigative Site | Hayward, California, United States | — |
| Novartis Investigative Site | La Jolla, California, United States | — |
| Novartis Investigative Site | Los Angeles, California, United States | — |
| Novartis Investigative Site | Montebello, California, United States | — |
| Novartis Investigative Site | Oakland, California, United States | — |
+ 215 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT00720941